The EORTC Board cordially invites you to a Plenary Session in honor of Francoise Meunier
At the Crowne Plaza Brussels - Le Palace on 12 March 2015 at 16:00
After 24 years of dedicated service as EORTC Director General with a major commitment to the management of pan-European cancer research, Françoise Meunier will continue her activities from 1st April 2015 as EORTC Director Special Projects.
Program
- General introduction - Roger Stupp (CH)
- Françoise Meunier’s implication in research on “Fungal infections” - Peter Donnelly (NL)
- Françoise Meunier as EORTC Director General - Alexander Eggermont (FR)
- The patients perspectives and survival issues - Isabelle Lebrocquy (NL)
- Cancer management and transatlantic cooperation - Richard Schilsky (USA)
- The EORTC Charitable Trust - Diego du Monceau de Bergendal (BE)
- EORTC future perspectives - Roger Stupp (CH)
Followed by a reception and walking dinner at Palais d’Egmont at 19:00
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
